• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Veracyte, Inc. - Common Stock (NQ:VCYT)

    59.85 +1.12 (+1.91%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,230,108
    Open 58.99
    Bid (Size) 59.31 (100)
    Ask (Size) 60.53 (100)
    Prev. Close 58.73
    Today's Range 58.75 - 60.71
    52wk Range 22.61 - 60.91
    Shares Outstanding 67,473,870
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally ↗
    This genomics diagnostics specialist, up over 120% in a year, reported a notable insider sale amid ongoing scheduled dispositions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    High Growth Momentum Breakout Setup: Veracyte Inc (NASDAQ:VCYT) ↗
    Via Chartmill

    Performance

    YTD
    +41.2%
    +41.2%
    1 Month
    +24.2%
    +24.2%
    3 Month
    +85.8%
    +85.8%
    6 Month
    +41.6%
    +41.6%
    1 Year
    +121.4%
    +121.4%

    More News

    Read More
    News headline image
    Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
    From Veracyte
    Via Business Wire
    News headline image
    ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
    From Veracyte, Inc.
    Via Business Wire
    Veracyte Inc (NASDAQ:VCYT) Smashes Q1 Estimates and Raises Full-Year Guidance, Shares Surge ↗
    Via Chartmill
    Veracyte Inc (NASDAQ:VCYT) GARP Analysis Reveals Strong Growth at a Reasonable Price ↗
    Via Chartmill
    News headline image
    Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
    From Veracyte
    Via Business Wire
    Veracyte Inc (NASDAQ:VCYT): A High-Growth Biotech Stock Poised for a Technical Breakout ↗
    Via Chartmill
    Veracyte Inc (NASDAQ:VCYT) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate ↗
    Via Chartmill
    Veracyte Inc (NASDAQ:VCYT) Posts Strong Q4 Earnings Beat and Positive 2026 Outlook ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Veracyte to Participate in Upcoming Investor Conferences
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
    From USA News Group
    Via GlobeNewswire
    News headline image
    Why Veracyte Stock Is Skyrocketing Higher This Week ↗
    Via The Motley Fool
    News headline image
    Veracyte (VCYT) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
    Via Chartmill
    News headline image
    Veracyte Announces First Quarter 2026 Financial Results
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
    From Veracyte, Inc.
    Via Business Wire
    Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
    Via Chartmill
    News headline image
    Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Names Kevin Haas as Chief Development and Technology Officer
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte (VCYT) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
    From Veracyte, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Veracyte, Inc. - Common Stock publicly traded?
    Yes, Veracyte, Inc. - Common Stock is publicly traded.
    What exchange does Veracyte, Inc. - Common Stock trade on?
    Veracyte, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Veracyte, Inc. - Common Stock?
    The ticker symbol for Veracyte, Inc. - Common Stock is VCYT on the Nasdaq Stock Market
    What is the current price of Veracyte, Inc. - Common Stock?
    The current price of Veracyte, Inc. - Common Stock is 59.85
    When was Veracyte, Inc. - Common Stock last traded?
    The last trade of Veracyte, Inc. - Common Stock was at 07/01/26 04:00 PM ET
    What is the market capitalization of Veracyte, Inc. - Common Stock?
    The market capitalization of Veracyte, Inc. - Common Stock is 4.04B
    How many shares of Veracyte, Inc. - Common Stock are outstanding?
    Veracyte, Inc. - Common Stock has 4B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.